XML 90 R74.htm IDEA: XBRL DOCUMENT v3.25.0.1
FAIR VALUE MEASUREMENTS - Narrative (Details)
 12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Contingent consideration, liability $ 282,212,000 $ 288,657,000 $ 306,927,000 $ 359,021,000
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount 5,102,000 5,093,000    
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount 16,850,000 15,071,000    
Other Current Liabilities        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Contingent consideration, liability 19,700,000      
Other Noncurrent Liabilities        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Contingent consideration, liability 262,500,000      
Venture Capital Investment Fund        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Investment owned, fair value 7,500,000 $ 5,200,000    
Committed capital 18,000,000.0      
Committed capital callable $ 10,900,000      
Weighted Average | Product Development and Other Milestone-based Payments | Measurement Input, Probability of Success        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Contingent consideration liability, measurement input 0.90 0.89    
Weighted Average | Product Development and Other Milestone-based Payments | Measurement Input, Present-value Factor        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Contingent consideration liability, measurement input 0.062 0.058    
Foreign Exchange Forward        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Derivative, notional amount $ 44,200,000 $ 39,500,000    
Derivative, fair value 0 0    
Gain (Loss) on Derivative Instruments, Net, Pretax 0      
Gain (Loss) on Derivative Instruments, Net, Pretax 0      
Thrive, Ashion and OmicEra | Fair Value        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Contingent consideration, liability $ 282,200,000 $ 288,700,000